---
document_datetime: 2025-12-02 06:32:35
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aranesp.html
document_name: aranesp.html
version: success
processing_time: 0.1153268
conversion_datetime: 2025-12-28 01:01:02.235676
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aranesp

[RSS](/en/individual-human-medicine.xml/67007)

##### Authorised

This medicine is authorised for use in the European Union

darbepoetin alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Aranesp](#news-on)
- [More information on Aranesp](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms. It is used in two groups of patients:

- adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly);
- adults who are receiving chemotherapy for non-myeloid cancer (cancer not originating in the bone marrow).

Aranesp contains the active substance darbepoetin alfa.

Expand section

Collapse section

## How is Aranesp used?

Aranesp can only be obtained with a prescription and treatment should be started by a doctor who has experience in treating the types of anaemia mentioned above.

Aranesp is available in a vial, a pre-filled syringe or a pre-filled pen. It is provided in various strengths.

For patients with chronic renal failure, Aranesp can be injected into a vein or under the skin. It must be injected under the skin in patients receiving chemotherapy. The dose and frequency of injection depend on why Aranesp is being used, and are adjusted, according to the patient's response, to obtain haemoglobin levels that remain within the recommended range (between 10 and 12 grams per decilitre). Haemoglobin is the protein in red blood cells that carries oxygen around the body. The lowest dose that provides adequate control of symptoms should be used.

Aranesp can be injected by the patient or their carer if they have been trained. For more information about using Aranesp, see the package leaflet or contact your doctor or pharmacist.

## How does Aranesp work?

In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of a hormone called erythropoietin, or by the body not responding well enough to erythropoietin. The active substance in Aranesp, darbepoetin alfa works in exactly the same way as the natural hormone to stimulate the production of red blood cells in the bone marrow. It is very slightly different in its structure to the natural hormone. Because of the slight changes to the structure, darbepoetin alfa remains in the body for longer than natural erythropoietin.

## What benefits of Aranesp have been shown in studies?

Aranesp has been shown to be effective in the treatment of chronic renal failure in four studies involving over 1,200 patients. Aranesp was as effective as human recombinant erythropoietin at increasing the haemoglobin levels and at keeping these levels maintained, whether given as an injection into a vein or under the skin.

Aranesp has also been studied in 124 children with chronic renal failure to check that it is absorbed in the same way as in adults.

In two studies involving 669 patients receiving chemotherapy, Aranesp was more effective than placebo (a dummy treatment) and fewer patients needed a blood transfusion.

## What are the risks associated with Aranesp?

In kidney failure patients, the most common side effects with Aranesp (which may affect more than 1 in 10 people) are hypersensitivity (allergy) and hypertension (high blood pressure) while in cancer patients the most common are hypersensitivity and oedema (fluid retention).

Aranesp must not be used in patients who have poorly controlled high blood pressure. For the full list of side effects and restrictions, see the package leaflet.

## Why is Aranesp authorised in the EU?

The European Medicines Agency decided that Aranesp's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Aranesp?

The company that markets Aranesp will provide educational packs for patients and healthcare professionals including information on how to self-inject the medicine, a training checklist and a demonstration device.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aranesp have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Aranesp are continuously monitored. Side effects reported with Aranesp are carefully evaluated and any necessary action taken to protect patients.

## Other information about Aranesp

Aranesp received a marketing authorisation valid throughout the EU on 8 June 2001.

Aranesp : EPAR - Medicine overview

English (EN) (80.72 KB - PDF)

**First published:** 07/11/2007

**Last updated:** 14/05/2019

[View](/en/documents/overview/aranesp-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-686)

български (BG) (112.74 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/bg/documents/overview/aranesp-epar-medicine-overview_bg.pdf)

español (ES) (80.77 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/es/documents/overview/aranesp-epar-medicine-overview_es.pdf)

čeština (CS) (104.22 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/cs/documents/overview/aranesp-epar-medicine-overview_cs.pdf)

dansk (DA) (79.03 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/da/documents/overview/aranesp-epar-medicine-overview_da.pdf)

Deutsch (DE) (81.5 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/de/documents/overview/aranesp-epar-medicine-overview_de.pdf)

eesti keel (ET) (78.54 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/et/documents/overview/aranesp-epar-medicine-overview_et.pdf)

ελληνικά (EL) (113.08 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/el/documents/overview/aranesp-epar-medicine-overview_el.pdf)

français (FR) (81.27 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/fr/documents/overview/aranesp-epar-medicine-overview_fr.pdf)

hrvatski (HR) (97.88 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/hr/documents/overview/aranesp-epar-medicine-overview_hr.pdf)

italiano (IT) (80.2 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/it/documents/overview/aranesp-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (107.77 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/lv/documents/overview/aranesp-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (101.73 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/lt/documents/overview/aranesp-epar-medicine-overview_lt.pdf)

magyar (HU) (99.72 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/hu/documents/overview/aranesp-epar-medicine-overview_hu.pdf)

Malti (MT) (105.04 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/mt/documents/overview/aranesp-epar-medicine-overview_mt.pdf)

Nederlands (NL) (80.59 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/nl/documents/overview/aranesp-epar-medicine-overview_nl.pdf)

polski (PL) (104.03 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/pl/documents/overview/aranesp-epar-medicine-overview_pl.pdf)

português (PT) (82.51 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/pt/documents/overview/aranesp-epar-medicine-overview_pt.pdf)

română (RO) (108.65 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/ro/documents/overview/aranesp-epar-medicine-overview_ro.pdf)

slovenčina (SK) (103.44 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/sk/documents/overview/aranesp-epar-medicine-overview_sk.pdf)

slovenščina (SL) (97.94 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/sl/documents/overview/aranesp-epar-medicine-overview_sl.pdf)

Suomi (FI) (79.12 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/fi/documents/overview/aranesp-epar-medicine-overview_fi.pdf)

svenska (SV) (79.19 KB - PDF)

**First published:**

07/11/2007

**Last updated:**

14/05/2019

[View](/sv/documents/overview/aranesp-epar-medicine-overview_sv.pdf)

Aranesp : EPAR - Risk-management-plan summary

English (EN) (50.68 KB - PDF)

**First published:** 14/05/2019

**Last updated:** 13/01/2020

[View](/en/documents/rmp-summary/aranesp-epar-risk-management-plan-summary_en.pdf)

## Product information

Aranesp : EPAR - Product Information

English (EN) (1.76 MB - PDF)

**First published:** 15/12/2009

**Last updated:** 28/06/2024

[View](/en/documents/product-information/aranesp-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-284)

български (BG) (2.33 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/bg/documents/product-information/aranesp-epar-product-information_bg.pdf)

español (ES) (2.13 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/es/documents/product-information/aranesp-epar-product-information_es.pdf)

čeština (CS) (2.33 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/cs/documents/product-information/aranesp-epar-product-information_cs.pdf)

dansk (DA) (2.13 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/da/documents/product-information/aranesp-epar-product-information_da.pdf)

Deutsch (DE) (2.17 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/de/documents/product-information/aranesp-epar-product-information_de.pdf)

eesti keel (ET) (2.11 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/et/documents/product-information/aranesp-epar-product-information_et.pdf)

ελληνικά (EL) (2.36 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/el/documents/product-information/aranesp-epar-product-information_el.pdf)

français (FR) (2.28 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/fr/documents/product-information/aranesp-epar-product-information_fr.pdf)

hrvatski (HR) (2.24 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/hr/documents/product-information/aranesp-epar-product-information_hr.pdf)

íslenska (IS) (2.12 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/is/documents/product-information/aranesp-epar-product-information_is.pdf)

italiano (IT) (2.18 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/it/documents/product-information/aranesp-epar-product-information_it.pdf)

latviešu valoda (LV) (2.24 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/lv/documents/product-information/aranesp-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.31 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/lt/documents/product-information/aranesp-epar-product-information_lt.pdf)

magyar (HU) (2.3 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/hu/documents/product-information/aranesp-epar-product-information_hu.pdf)

Malti (MT) (2.6 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/mt/documents/product-information/aranesp-epar-product-information_mt.pdf)

Nederlands (NL) (2.15 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/nl/documents/product-information/aranesp-epar-product-information_nl.pdf)

norsk (NO) (2.13 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/no/documents/product-information/aranesp-epar-product-information_no.pdf)

polski (PL) (2.33 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/pl/documents/product-information/aranesp-epar-product-information_pl.pdf)

português (PT) (2.26 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/pt/documents/product-information/aranesp-epar-product-information_pt.pdf)

română (RO) (2.37 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/ro/documents/product-information/aranesp-epar-product-information_ro.pdf)

slovenčina (SK) (2.31 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/sk/documents/product-information/aranesp-epar-product-information_sk.pdf)

slovenščina (SL) (2.24 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/sl/documents/product-information/aranesp-epar-product-information_sl.pdf)

Suomi (FI) (2.12 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/fi/documents/product-information/aranesp-epar-product-information_fi.pdf)

svenska (SV) (2.12 MB - PDF)

**First published:**

15/12/2009

**Last updated:**

28/06/2024

[View](/sv/documents/product-information/aranesp-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG1743 28/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aranesp : EPAR - All Authorised presentations

English (EN) (26.4 KB - PDF)

**First published:** 12/05/2009

**Last updated:** 29/03/2011

[View](/en/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-770)

български (BG) (122.03 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/bg/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.2 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/es/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_es.pdf)

čeština (CS) (101.63 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/cs/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.34 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/da/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.4 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/de/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.26 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/et/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (100.65 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/el/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_el.pdf)

français (FR) (28.24 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/fr/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (132.9 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/hr/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (66.89 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/is/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.59 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/it/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (103.79 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/lv/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (101.69 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/lt/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (101.43 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/hu/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (109.55 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/mt/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.2 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/nl/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.48 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/no/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_no.pdf)

polski (PL) (107.79 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/pl/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.46 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/pt/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_pt.pdf)

română (RO) (99.08 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/ro/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (99.15 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/sk/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (69.57 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/sl/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.86 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/fi/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.25 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

29/03/2011

[View](/sv/documents/all-authorised-presentations/aranesp-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aranesp Active substance darbepoetin alfa International non-proprietary name (INN) or common name darbepoetin alfa Therapeutic area (MeSH)

- Anemia
- Cancer
- Kidney Failure, Chronic

Anatomical therapeutic chemical (ATC) code B03XA02

### Pharmacotherapeutic group

Other antianemic preparations

### Therapeutic indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.

Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/000332 Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 01/05/2001 Marketing authorisation issued 08/06/2001 Revision 46

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aranesp : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (398.6 KB - PDF)

**First published:** 15/12/2009

**Last updated:** 28/06/2024

[View](/en/documents/procedural-steps-after/aranesp-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Aranesp-H-C-332-X-0042 : EPAR - Assessment Report - Extension

English (EN) (137.79 KB - PDF)

**First published:** 23/09/2008

**Last updated:** 23/09/2008

[View](/en/documents/variation-report/aranesp-h-c-332-x-0042-epar-assessment-report-extension_en.pdf)

Aranesp-H-C-332-II-0035 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (123.13 KB - PDF)

**First published:** 09/10/2007

**Last updated:** 09/10/2007

[View](/en/documents/scientific-discussion-variation/aranesp-h-c-332-ii-0035-epar-scientific-discussion-variation_en.pdf)

Aranesp-H-C-332-II-0028 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (117.62 KB - PDF)

**First published:** 14/06/2006

**Last updated:** 14/06/2006

[View](/en/documents/scientific-discussion-variation/aranesp-h-c-332-ii-0028-epar-scientific-discussion-variation_en.pdf)

Aranesp : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (93.74 KB - PDF)

**First published:** 14/06/2006

**Last updated:** 14/06/2006

[View](/en/documents/steps-after-cutoff/aranesp-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Aranesp : EPAR - Scientific Discussion

English (EN) (353.6 KB - PDF)

**First published:** 14/06/2006

**Last updated:** 14/06/2006

[View](/en/documents/scientific-discussion/aranesp-epar-scientific-discussion_en.pdf)

Aranesp : EPAR - Procedural steps taken before authorisation

English (EN) (88.68 KB - PDF)

**First published:** 14/06/2006

**Last updated:** 14/06/2006

[View](/en/documents/procedural-steps/aranesp-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Aranesp

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

#### More information on Aranesp

- [EMEA-000329-PIP02-09-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000329-pip02-09-m05)
- [Aranesp - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/aranesp)
- [Use of Erythropoiesis Stimulating Agents (ESAs) in Patients Receiving Myelosuppressive Chemotherapy in Europe and the UK (20190404) - post-authorisation study](https://catalogues.ema.europa.eu/study/50771)
- [Use of Erythropoiesis Stimulating Agents (ESA) in Patients With Non-myeloid Malignancies Receiving Myelosuppressive Chemotherapy 2014 - 2021 (20170210) - post-authorisation study](https://catalogues.ema.europa.eu/study/28521)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/06/2024

## Share this page

[Back to top](#main-content)